ADIPOSE TISSUE. METABOLIC ALTERATIONS AND EFFECT OF MICROBIOTA by Palacio Miranda, Juan Carlos & Iturralde Navarro, María











METABOLIC ALTERATIONS  
AND 
EFFECT OF MICROBIOTA 
 
Author: 
Juan Carlos Palacio 
 
Director: 
María Iturralde Navarro 
 
Faculty of Science – Biotechnology Degree 
2020-2021 







2.1. Obesity: a deadly disease  




5.1. White, brown and beige adipocytes 
5.2. Adipogenesis  
5.3. Inflammation and fibrosis  
5.4. Adipokines  
6.METABOLIC ALTERATIONS 
6.1. Obesity and CVDs 
6.2. Obesity and T2DM 
6.3. Progression of T2DM increasing the risk of CVD 
7.CHANGES IN MICROBIOTA 
8.OBESITY AND COVID-19 









Obesity is among the top health concerns across the globe, and it has been for many years, 
yet the world remains unable to stop it. Overweight and obesity follow a clear uptrend pattern 
and that will not change unless a real battle is waged against their main causes.  
 
The present review will explore the causes and mechanisms underlying this health crisis, 
focusing on what for many years has been disregarded: the active role that the adipose tissue 
plays in the development of the metabolic alterations regarding obesity and the undeniable 
implication of gut microbiota in supporting the existing mechanisms for weight gain and fat 
storage. The aim is to integrate most of the factors to provide a global vision of the processes 
happening obesity.  
 
The review has been methodically elaborated, bringing together information from many 
different experts in the different fields, striving for accurate and state-of-the-art information 
throughout the whole review, with special emphasis in the final fragment on the other major 
health crisis concerning the world right now: COVID-19. 
 
La obesidad es uno de los mayores problemas globales a nivel sanitario y lleva siéndolo varios 
años sin que el mundo haya podido frenarlo. La incidencia del sobrepeso y de la obesidad 
siguen un claro patrón ascendente que no cambiará a no ser que realmente se ataquen las 
principales causas. 
 
Esta revisión bibliográfica explorará las causas subyacentes a esta crisis de salud, 
centrándose en lo que durante muchos años se ha descuidado: el papel activo que juega el 
tejido adiposo en el desarrollo de las alteraciones metabólicas de la obesidad y la innegable 
implicación de la microbiota intestinal en el apoyo los mecanismos existentes para el aumento 
de peso y el almacenamiento de grasa. El objetivo es integrar la mayoría de los factores para 
brindar una visión global de los procesos que ocurren en la obesidad. 
 
La revisión ha sido elaborada metódicamente, reuniendo información de muchos expertos de 
los diferentes campos, buscando información precisa y de actualizada a lo largo de toda la 
revisión, con especial énfasis en el fragmento final sobre la otra gran crisis de salud mundial 




2.1. Obesity: a deadly disease 
 
Obesity and overweight are defined by the World Health Organization (WHO) as abnormal or 
excessive fat accumulation that may impair health. They are most commonly discerned and 
measured through the BMI or Body Mass Index, which is the result of the weight of a person 
divided by the square of his or her height in meters (
𝑘𝑔
𝑚2
). To be precise, the condition of 
overweight in adults ranges from a BMI equal or greater than 25 to a BMI of 30. Once the BMI 
is equal or greater than 30 it is classified as obesity1. 
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Obesity is among the top health concerns across the globe2 and it has been for many years, 
yet the world remains unable to stop it. Overweight and obesity follow a clear uptrend pattern 
and that will not change unless a real battle is waged against their main causes. The latest 
Centers and Disease Control and Prevention (CDC) report on health conditions by age shows 
some astonishing numbers. In the United States, from the years 1988- 1944 to the years 2017-
2018, the percentage of obesity in adults has risen from 22.5% to 42.2%. The percentage in 
children has seen an increase of approximately 9%3.  
 
The problem is not exclusively of the United States. In Spain, the Agencia Española de 
Seguridad Alimentaria y Nutrición (AESAN) reports that 52.7% of the adult population is 
overweight and 17.3% is obese. In children the numbers do not improve as around 42% of 
them are overweight and around 18% are obese4. 
 
To gain some worldwide perspective on the issue, the WHO showcases a series of key facts 
to help understand the magnitude of obesity. According to the statistics dating 1st April 2020, 
worldwide obesity has tripled since 1975. This striking increase can be appreciated in 
comparative color-coded maps (Fig. 1). In 2016 more than 1.9 billion adults were overweight; 
of these, over 650 million were obese. This means that 39% of adults were overweight and 




 Figure 1. Adapted from: Age-standardized mean BMI in women by country in 1975 and 20145 
 
This data is extremely worrying because obesity is a disease that takes a toll on both the 
healthcare system funds and the individual suffering from it. Besides the social disabilities 
resulting from the stigma associated with obesity6, the most common health consequences of 
overweight and obesity are cardiovascular issues1, especially heart disease and strokes, type 
2 diabetes, for which obesity is the leading risk factor7. Also, musculoskeletal disorders and 
some cancers are acknowledged as direct consequences of obesity. More insight about the 
inner mechanisms will be presented later.   
 
The rise of overweight and obesity has two main causes: certain food marketing practices and 
institutionally-driven reductions in physical activity. However, further investigation has 
revealed at least ten putative factors that may require more attention that they are receiving 
now. These factors are microbiota microorganisms, epigenetics, increasing maternal age, 
greater fecundity among people with higher adiposity, assortative mating, sleep debt, 
endocrine disruptors, pharmaceutical iatrogenesis, reduction in variability of ambient 
temperatures, and intrauterine and intergenerational effect8.  
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The most remarkable and proven cause is the diet changes and the food marketing associated 
with certain types of products. These changes mainly involve the sweetening of the diet, 
especially beverages. Data shows that in the United States indicate that 74% of products in 
the food supply contain sweeteners. This impacts the rest of the world’s supply and, although 
governments are taking steps in the right direction, it is suggested that they keep adapting and 
improving the measures, since the excessive intake of added sugars has adverse effects on 
the consumer’s health9.  
 
There are several key genetic, molecular and physiological mechanisms involved in obesity, 
which will be discussed thereafter. 
 
2.2 Obesity: mechanisms involved 
 
There are several hypotheses about the genetic contribution to obesity, such as the fetal 
programming, which postulates that the predominant governing force is the fetal environment, 
meaning that if there is a maternal over or undernutrition it will provoke a corresponding 
postnatal response. This hypothesis would be supported by epigenetic mechanisms. Other 
theories involve evolutionary pressure, such as the predation release theory, which explains 
the contribution through the absence of predators, making obesity genes thrive in this 
favorable environment. Alongside these favorable environment theories are the sedentary 
lifestyle and the increased reproductive fitness and the assortative mating. The most plausible 
explanation is a complex one, combining all the others mentioned above10. The power of 
Genome-Wide Association Studies (GWAS) is revealing a large quantity of obesity related 
minor genes, meaning that they have a small effect size on BMI11. Despite of all the new 
technology and findings, explaining the apparent high heritability of obesity still poses a 
challenge. 
 
Although the genetic contribution plays a big role, one must not forget that the origin of the 
obesity pandemic are indisputably the changes in diet and lifestyle.  
 
There are other important mechanisms that revolve around the adipose tissue, how it grows 
in response to excessive caloric intake, how there are processes of inflammation and fibrosis 
taking place and how it synthesizes and secretes adipokines that act in different parts of the 
human body. All of these eventually cause metabolic alterations that will be further discussed. 
 
Finally, the last type of mechanisms that have a proven impact on obesity are the ones 
triggered and regulated by the microbiota. The microbiota suffers changes through the process 






The aim of this work is to show which are the most important mechanisms involved in obesity 
as well as to highlight the role of the adipose tissue. For years this tissue has been thought to 
have little activity, however recently its implication in body mass regulation cannot be ignored. 
Some aspects of the implication of microbiota are also discussed and lastly the possible 
association between obesity and severity of COVID-19 cases. 





In a review, the bibliographic search must be thorough, objective and reproducible. These 
three characteristics are desirable in any work; although there must be a balance between the 
number and the relevance of the articles selected. There should be enough material to 
properly inform the researcher but not so much that the researcher cannot process it12.  
The selection criteria for this work have been:  
 
 Publishing date, aiming for recent studies, with few exceptions regarding already fully 
characterized mechanisms. 
 
 Keywords, such as “obesity”, “adipocytes”, “adipokines”, “microbiota”, “COVID-19” and 
several more that appear throughout the work. The search of these words and their 
combinations has been proven vital in order to find suitable results. 
 
 Database in which the article is published, selecting only those coming from verified 
databases such as PubMed or Nature. 
 
 
5. ADIPOSE TISSUE 
 
The classic concept of the adipose tissue as an inert fat storage has been forgotten and 
replaced by a new updated vision. The adipose tissue is a very dynamic endocrine organ 
capable of having an impact on the metabolism of the whole body13. This is possible thanks 
to the hormones it produces and secretes, the adipokines. However, it does not always work 
as it should, causing what is known as an adipose tissue dysfunction. This condition has been 
proposed to be the underlying cause of metabolic alterations such as type 2 diabetes14. 
 
 5.1. White, brown and beige adipocytes 
 
Traditionally, adipocytes have been divided in two categories attending to morphology and 
function: white and brown. On one hand white adipocytes are big rounded cells with a 
unilocular lipid droplet, surrounded by a thin layer of cytoplasm, few mitochondria and a 
flattened nucleus (Fig. 2a). Their main functions are energy storage, heat insulation and 
secretion of adipokines. White adipose tissue is distributed mostly in the subcutaneous 
compartment but can also be found covering organs such as the liver, the kidneys and even 
muscle. On the other hand, brown adipocytes are smaller, polygonal shaped, with multiple 
lipid droplets, several mitochondria and a central nucleus (Fig. 2b). They are responsible for 
the adaptive thermogenesis through the UCP-1 protein. Brown adipose tissue can also store 
energy and secrete adipokines, although less efficiently than white adipose tissue. Contrary 
to white adipocytes, brown ones have very specific locations: cervical, supraclavicular, 
periaortic, paravertebral and suprarenal15. 
 
In 2010 a third type of adipose cells was described, the beige adipocytes (Fig. 2c). These are 
brown-like adipocytes inside white adipose tissue, their importance lies in two main reasons, 
understanding how environmental factors control cell fate specification and the possibility of 
them being a new therapeutic target in the treatment of obesity and other metabolic 
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disorders16. The acquisition of this phenotype is brought by factors such as cold exposure17, 
stimulation of β-adrenergic receptors and peroxisome proliferator-activated receptor-γ (PPAR-
γ). This phenotype acquisition process is known as fat browning15. Similar to brown 
adipocytes, they are defined by their multilocular lipid droplet morphology, high mitochondrial 
content and the expression of a core set of brown fat–specific genes18. 
 
Despite of how similar beige and brown may seem at first glance, since both have the common 
ability to undergo thermogenesis, there are several differences that set them apart as distinct 
cell types. For instance, they derive from different embryonic precursor, there are also a 
number of quantitative trait loci associated with the induced development of beige but not 




a. White Adipose Tissue b. Brown Adipose Tissue c. Beige Adipose Tissue 
Figure 2. White, brown and beige adipose tissue. Representative histologic sections of mice tissue. Hematoxylin 
and eosin staining, 100X 15.  
 
Beige adipocytes express several differential genetic markers like CD137, TMEM26, TBX1 or 
SHOX215 as well. Moreover, a notorious difference exists between how both of these cell types 
regulate the expression of the uncoupling protein-1 (UCP1). Brown adipocytes express high 
levels of UCP1 in basal or unstimulated conditions whereas beige adipocytes do not. In order 
for the beige adipocytes to express UCP1, they need certain stimuli or activators such as 
agonists of the β-adrenergic receptors or PPAR-γ18.  
 
The UCP1 is a protein located in the internal membrane of the mitochondria which confers the 
protons permeability to pass through that membrane, thus causing the uncoupling of the 
respiratory chain from the oxidative phosphorylation process. This phenomenon shifts the 
energy that the respiratory chain uses to establish a proton gradient into producing heat 
instead of producing ATP. This heat production process called thermogenesis needs a large 
oxidation rate to be sustained, for this purpose there is a big intake of metabolic substrates, 
fundamentally fatty acids and glucose from the bloodstream19.  
 
In conclusion, brown and beige adipocytes can undergo thermogenesis, therefore consuming 
a lot of metabolites and helping prevent overweight and obesity. The remarkable difference is 
that beige can be induced and brown cannot. As previously stated, new experiments are on 
the way to determine whether they can be used as a therapeutic target or not. It is key to 
understand the roles of each type of adipocyte to further comprehend the mechanisms that 
will be described below. 
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5.2. Adipogenesis  
 
Adipogenesis refers to the process of differentiation of pre-adipocytes into mature fat cells, in 
other words, the development of adipose tissue. It varies a little depending on age and sex, 
however the determinant factor for fat accumulation is the balance between fat synthesis or 
lipogenesis and fat breakdown or lipolysis. Fat synthesis occurs when the balance is altered 
in favor of high caloric intake, in this situation, the body must store the leftover energy.  
 
The molecular basis for adipogenesis can be looked at as a process divided in two phases. 
The first phase is the commitment phase, where a fibroblast-like cell such as a mesenchymal 
precursor commits to the adipocyte lineage without any morphological changes, forming what 
is known as a preadipocyte. The main factors involved in this phase are the bone morphogenic 
proteins 2 and 4 (BMP2 and BMP4)20. They drive adipocyte commitment through their 
receptor, which simultaneously activates a new transcription factor family called Small Mothers 
Against Decapentaplegic (SMAD). When the heterodimers SMAD1, SMAD5 and SMAD8 are 
activated they activate SMAD4 (also known as DPC4)21. Finally, this part of the signaling 
pathway is completed when SMAD4 stimulates the expression of peroxisome proliferator-
activated receptor-γ (PPARγ), which truly is the master regulator of the adipogenesis process. 
 
The second phase is the differentiation phase; it starts from PPARγ. PPARγ is indispensable 
for the differentiation since it activates C/EBPα (CCAT-enhancer-binding protein-α) and 
together they fully activate the transcription of mature adipocyte specific genes such as the 
insulin receptor gene, the adiponectin gene and the Adipocyte Protein 2 (aP2) gene, also 
known as Fatty Acid Binding Protein 4 (FABP4)22. 
 
Some other studies make the point that this process has three steps, adding one in the middle 
of the two described above. This intermediate step would be the mitotic clonal expansion, 
involving DNA replication and duplication of cells23. 
 
Certain extracellular factors influence whether an adipocyte differentiates or not. There are 
signaling molecules that include including insulin24, glucocorticoids25 and bone morphogenetic 
proteins (BMPs) that directly activate PPARγ, thus facilitating the differentiation. On the other 
hand, there are also ligands that cause insulin resistance and prevent the precursor cells from 
undergoing differentiation such as interleukin 1β (IL-1β) and interleukin 6 (IL-6), transforming 
growth factor-β (TGF-β) or tumor necrosis factor (TNF).  
 
There also exist physiological states and cues that are integrative of the whole body and 
influence the regulation of adipogenesis. Among these are inflammation, which will be detailed 
later; the circadian rhythm, which if disrupted, increases the risk of obesity26 due to a 
deregulation of the cyclic expression of PPARγ; and lastly the reactive oxygen species (ROS), 
if they exceed the limit that the cells can process, they can cause what is known as oxidative 
damage27 since they oxidize lipids and amino acids, ultimately leading to inefficient ATP 
production and metabolic dysfunction28. 
 
This increase or expansion of the adipose depots can be either in size (hypertrophy) or in 
number (hyperplasia). Hyperplasia is usually considered the healthiest of the two, for it allows 
the tissue to maintain proper vascularization and adipokine levels14. On the other hand, 
hypertrophy is linked to hypoxia in the tissue due to a massive size increase (Fig. 3). The 
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response to hypertrophy carried out by the adipose tissue involves hypoxia-inducible factor 1 
or HIF-1, it is however insufficient to induce enough vascularization.  
 
Instead, the hypoxic adipose tissue cells increase the expression of pro-fibrotic genes, leading 
to tissue fibrosis. In this process, the hypoxic adipose tissue can go as far as undergoing 
necrosis, which leads to posterior infiltration by immune cells and consequently tissue 
inflammation28. All of the previous factors pile up to end up decreasing adipose tissue function, 
causing high levels of sugars and lipids in the blood circulation and thus contributing to 




Figure 3. Mechanisms of adipose tissue expansion. When the balance between expenditure and intake tips in 
favor of the intake, leftover energy needs to be stored. On the one hand, hyperplasia is associated with healthy 
storage, proper vascularization and no circulating abnormalities. On the other hand, hypertrophy is linked to fibrosis, 
hypoxia, inflammation and even necrosis of the adipose tissue, as well as increased concentrations of lipids and 
glucose in circulation 28. 
 
5.3. Inflammation and fibrosis 
 
As previously discussed, the adipose tissue can grow in an unhealthy fashion. This causes an 
adipose dysfunction characterized by inflammation and fibrosis processes.  
 
Inflammation is defined as a protective tissue response to injury or destruction of tissues. 
Triggered by hypoxia, chronic inflammation is a characteristic feature of obesity and metabolic 
alterations. This kind of inflammation aims for the proliferation of blood vessels to fight against 
the hypoxic state, and it includes the presence of lymphocytes and macrophages. It is also 
associated with certain inflammatory adipokines. The main inflammatory markers are   
interleukin 6 (IL-6) and C-reactive protein (CRP); in opposition to these and as the main anti-
inflammatory marker the human body produces adiponectin29. All of these play a huge role as 
links between inflammation and obesity. 
 
Interleukin 6 is a pro-inflammatory cytokine produced not only by the white adipose tissue but 
also by other cell types such as immune cells. This is a special cytokine because its effects 
occur at sites different from its origin. The mechanism involves the interleukin 6 receptor (IL-
6R), which is also expressed in the hypothalamus, controlling appetite and energy intake30.  
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Macrophages are the main cell type infiltrating the adipose tissue and raise the levels of IL-6. 
Increased IL-6 levels cause a series of complications, especially related to cardiovascular 
diseases, different kinds of cancer and other diseases such as pulmonary hypertension, 
chronic renal diseases and even depression.  
 
C-reactive protein (CRP) is a sensitive marker of systemic inflammation that is synthesized by 
the liver. Although it is not obesity specific, it is obesity related. Many analyses have found 
strong evidence that links every degree of obesity directly to CRP31. This correlation is not 
affected by ethnicity characteristics and sex. The physiological mechanism is well described 
for this association. The liver drains free fatty acids and triacylglycerol, inducing the release of 
cytokines such as IL-6 by the adipose tissue. This event triggers expression and release of 
CRP by the hepatocytes, which explains the elevated levels. This mechanism also links IL-6 
and CRP as pro-inflammatory markers related to obesity29. 
 
Opposing the inflammatory effects of IL-6 and CRP is the adiponectin. Adiponectin is a protein 
hormone derived from adipocytes. It has been identified as having a positive impact on not 
only inflammation but also atherosclerosis, type 2 diabetes and insulin resistance; all of them 
being possible consequences derived from obesity. It circulates at fairly high serum 
concentrations (2–20 µg/ml) in healthy individuals.  
 
It plays an important autocrine role helping fat tissue mass grow in a hyperplasic way rather 
than in a hypertrophic way32. Other important local effect is the increase of local nitric oxide 
production and the inhibition of plaque initiation and thrombosis. This offers protection against 
endothelial dysfunction and reduced oxidative stress. Adiponectin also has effects in the liver, 
improving insulin sensitivity, reducing gluconeogenesis and increasing the oxidation process. 
All of the previous actions amount to a substantial positive impact on metabolic alterations. In 
obesity, adiponectin levels in the serum are found to be significantly reduced33, and it is 
assumed that the high levels of inflammatory markers such as IL-6 are the cause for the 
reduction of synthesis and secretion of adiponectin. 
 
The three molecules described are key when it comes to understanding the inflammatory 
process that the adipose tissue goes through in obese conditions. However, they are not the 
only ones, the mechanism controlling inflammation is complex and it involves local and central 
levels of regulation.  
 
Fibrosis is defined as the accumulation of excessive extracellular matrix (ECM). It is a 
process that can occcur in the liver, heart, kidney and also in the adipose tissue. It is likely 
that they all have equal negative impact on systemic metabolic alterations. This 
phenomenom happens in rapidly expanding adipose tissue, where the hypoxia caused by 
hypertrophy leads to the induction of the expression of the triggering molecule, the hypoxia-
inducible factor 1α (HIF-1α). Among other functions realted to the inflammation pathway, 
HIF-1α leads to a profibrotic transcriptional program in the adipose tissue34.  
 
ECM is mainly constituted by fibronectin and collagens. Type I collagens account for most of 
the framework necessary to sustain ECM, however it is type IV collagen which stabilizes the 
complex. Studies suggest that the excess of type IV collagen is a determinant factor in 
metabolyc dysregulations35. Also the presence of lysyl oxidase (LOX) is crucial for collagen 
fibre crosslinking and thus for fibrosis development36.  




Adipose tissue cells encapsulated in ECM lose their functions and undergo necrosis more 
frequently. The remaining lipid droplets stay in the tissue for weeks and along with 
surrounding dysfunctional adipose tissue cells, they induce the infiltration of macrophages 
and other white cells, thus enabling a pro-inflammatory environment (Fig. 4.1). Other studies 
suggest that HIF-1α by itself is a direct inducing factor of different pro-inflammatory 
molecules, for example IL-6 which has been previously described and causes white cell 




Figure 4. Proposed models for the sequential steps leading to adipose tissue fibrosis and metabolic dysfunction. 
Obese fat pad expansion quickly leads to a hypoxic state. As a result, HIF1a is induced. The first hypothesis 
proposes that the adipose cells encapsulated in excessive extracellular matrix lose their functions and undergo 
necrosis, leaving behind remaining lipid droplets, which along with dysfunctional adipocytes surrounding them 
recruit macrophages, leading to a pro-inflammatory state and ultimately causing fibrosis. The second hypothesis 
suggests that HIF-1 α by itself has the capacity of inducing pro-inflammatory molecules, causing the macrophage 
infiltration and therefore ending in fibrosis. Both hypothesis reach the same outcome in the end and both seem 
plausible, the reality is keen to be a combination of the two. 
 
 
Fibrosis has not only been associated with dysfunctional adipose tissue but also to insulin 
resistance and it is a substantial risk factor that can lead to type 2 diabetes along with the 




Adipokines can be defined as the specific cytokines of adipocytes. They are associated with 
the progression of obesity and linked consequences. Adipokines have hormone function, act 
as growth factors that modulate insulin resistance, and act on the fat and glucose metabolism 
while also participating in pro and anti-inflammatory responses; they act in paracrine and 
endocrine manners. When there is an excess of adiposity and adipose tissue dysfunction, 
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adipokines are also deregulated, influencing in a negative fashion other cytokine and 
chemokine secretions and interfering with glucose and lipid metabolism37.  
 
The main adipokines include leptin, adiponectin, resistin, tumor-necrosis factor (TNF), 
interleukin 6 (IL-6), chemokine ligand 2 (CCL2), interleukin 10 (IL-10) and transforming growth 
factor-β (TFG-β). IL-6 has already been detailed and the rest will be further explained below 
(See annexe). 
 
Leptin is a peptide hormone, product of the LEP gene and secreted by white adipocytes38. 
Once released into the circulation, has central and peripheral effects by binding to the leptin 
receptor, which activates the JAK/STAT pathway. In the hypothalamus, where this receptor is 
widely expressed, it acts appetite-regulating factor that induces a decrease in food intake and 
an increase in energy consumption by inducing anorexigenic factors and suppressing 
orexigenic neuropeptides. Leptin also has effects on the periphery, increasing basal 
metabolism, influencing insulin secretion and reproductive function and being absolutely 
crucial for the modulation of the innate and the adaptive immunity39. 
 
Adiponectin is encoded by the ADIPOQ gene, and it binds to two receptors, AdipoR1 and 
AdipoR2, involved in the increase of expression of adenosine monophosphate kinase and 
PPARγ respectively. As previously described, it reduces inflammation and increases insulin 
sensitivity, the latter especially in the liver40. 
 
Resistin (RETN) differs from others because in humans it is secreted by macrophages. Its 
name comes from its capacity to interfere with the action of insulin. Decorin, a connective 
tissue extracellular matrix protein, has been deemed to be the probable receptor for murine 
RETN. No receptors in humans have been clearly identified at this time and the molecular 
mechanism by which RETN carries out its effects is not yet clear. Interestingly there are 
studies that suggest no correlation between RETN levels in obesity, meanwhile others report 
a notable increase of RETN levels associated with obesity40. What it is known is that, at least 
in rodent models, it activates pro-inflammatory cytokines via NFκB pathway and also activates 
the suppressor of cytokine signaling 3 (SOCS-3), which is acknowledged for reducing insulin 
signaling in adipose tissue and other tissues41. It is worth noting that NFκB is a well-known 
factor involved in diet-induced obesity, insulin resistance and the inflammation related to 
unhealthy adipose-tissue expansion. 
 
TNF is an inflammatory adipokine originally synthesized as a transmembrane monomer 
(TNFm) and is later processed by the TNF-converting enzyme resulting in soluble TNF (TNFs). 
Both forms have biological effects, however TNFm is thought to mediate autocrine actions and 
TNFs is responsible for the endocrine actions42. 
 
TNF is the factor originated from the adipose tissue linking obesity, inflammation and diabetes. 
The main source of TNF in obese individuals are not the adipocytes but the macrophages, 
that is the cause why elevated levels of TNF are observed in these individuals with metabolic 
syndrome43. The association between high levels of TNF and metabolic syndrome is the effect 
TNF has in mediating insulin resistance. The mechanism is not fully elucidated, but there is 
evidence that several downstream mediators of different inflammatory and metabolic diseases 
intersect. It is also known that TNF is involved in expression of other pro-inflammatory 
adipokines such as IL-6, CCL2 and TNF itself, through NFκB activation44.  




CCL2 is a chemokine produced mainly by macrophages and endothelial cells that participates 
in inflammation by recruiting monocytes toward the inflammatory site ref69. Studies have 
demonstrated that CCL2 expression has direct correlation with an increase of infiltration of 
pro-inflammatory cells in adipose tissue, therefore influencing insulin resistance and other 
metabolic disorders in obese humans40.  
 
IL-10 is produced by different types of immune cells and also adipocytes, creating an anti-
inflammatory environment in the adipose tissue under physiological conditions. ref 54. This 
adipokines plays a key role limiting inflammation through several mechanisms, such as 
inhibition of macrophage activity and inhibition of the synthesis of some pro-inflammatory 
cytokines, for example TNF which has been previously detailed. It does so by suppressing 
two subunits of NFκB, inducing an overall anti-inflammatory state and helping restore insulin 
sensitivity40.  
  
TGF-β is a global cytokine which almost all cells can produce and respond to. It regulates 
several cellular processes including but not limited to differentiation, proliferation, death and 
migration. TGF-β levels on adipose tissue are correlated to obesity45, however the exact role 
in obesity and adipogenesis has not been described yet. 
 
The main takeaway is that the adipose tissue is an incredible dynamic tissue, with a complex 
regulation and an extremely important endocrine function that affects the whole body. All of 
the processes that occur are connected at some point (Fig. 5) and form a delicate equilibrium 
that if disrupted, causes dysfunction and ultimately leads to obesity and metabolic alterations. 
 
 
Figure 5. STRING protein network interaction portraying the main adipokines described and their connections. 
Based on strong evidence of interaction, the network suggests a functional cluster formed by TNF, IL-10, IL-6, 
CCL2 and RETN. It can also be inferred that leptin, resistin and adiponectin work closely to carry out their function46. 
 
 
6. METABOLIC ALTERATIONS 
 
When the obesity related alterations presented above take a toll on the body, they are 
considered metabolic alterations or diseases. These are the cause why many obese 
individuals have a decreased quality of life or even die. They are all direct consequences 
derived from obesity, therefore preventable in many cases. The main diseases induced by 
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obesity include but are not limited to: cardiovascular diseases (CVDs), type 2 diabetes 
(T2DM), dyslipidemia, hypertension47 and in some cases different types of cancer.  
 
6.1 Obesity and CVDs 
 
CVDs are the leading cause of mortality among obese population, the excess of adipose tissue 
creates a pro-inflammatory profile due to adipokine deregulation, as previously discussed in 
this work. Its importance lies in the fact that this profile causes a relevant increase in CDVs 
risk regardless of other pathologies. Studies suggest that it may even alter myocardium 
structure and function48. This situation also influences dyslipidemia, T2DM, and hypertension, 
accelerating their progression and increasing their severity. Although adipokine profiles 
oscillates between individuals, the overproduction of pro-inflammatory is especially favored in 
obesity.  
 
Substantial weight gain and excess of adipose tissue is pernicious to metabolic health and a 
serious risk factor for the development of CVDs. Particularly in children, it causes abnormal 
glucose metabolism (hyperglycemia) and dyslipidemia, making them predisposed to develop 
CVDs and T2DM, which will severely impact their later stages of life37. Experimental studies 
have strongly associated increases in BMI with augmented risk of suffering from CVDs in the 
years to come; even the smallest increase in BMI has posterior consequences49.   
 
6.2 Obesity and T2DM 
 
Obesity is a primary cause of T2DM a chronic and metabolic disease characterized by 
elevated levels of blood glucose, which leads over time to damage to the heart, vasculature, 
eyes, kidneys and nerves. It is a condition marked by deficient insulin secretion by pancreatic 
islet β-cells, tissue insulin resistance and an inadequate compensatory insulin secretory 
response. The progression of this disease makes insulin secretion unable to maintain glucose 
homeostasis, which produces hyperglycemia. Individuals suffering from T2DM are mostly 
obese. In this condition. 
 
Insulin is a hormone produced in the β cells of the islets of Langerhans in the pancreas. It is 
released into the bloodstream in situations of hyperglycemia. The main regulator of insulin is 
glucose, however it can also be influenced by amino acids, ketones, incretins or different 
neurotransmitters.  
 
When the glucose transporter 2 (GLUT2) allows glucose into the β cells of the pancreas the 
signaling cascade is generated and ends with the secretion of insulin into the bloodstream. 
Insulin will travel through the circulation, being recognized by receptors of the tyrosine kinase 
family, whose binding and recognition will result in increased expression of glucose transporter 
proteins in the cell membrane50. As glucose regulates insulin, insulin is the key regulator of 
the metabolic balance of glucose. Low concentrations of insulin decrease liver and muscle 
glycogen synthesis and glucose uptake by sensitive tissues, while increasing lipolysis and 
gluconeogenesis. On the contrary, high concentrations of insulin cause a rapid uptake, use 
and storage of glucose by most of the tissues of the body, inducing protein, glycogen and 
protein synthesis. High levels of insulin also partake in the regulation of various genes in cells 
that respond to insulin, and inhibit hepatic gluconeogenesis51. 
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Insulin resistance (IR) can be defined as resistance to effects on glucose uptake, metabolism, 
or storage. Manifestations include but are not limited to decreased glucose transport and 
metabolism especially in adipocytes and muscle tissue; and diminished suppression of hepatic 
glucose output. Insulin affects primarily the metabolism of lipids and carbohydrates, however 
it is not dilucidated whether it affects protein metabolism or not. Different older studies have 
suggested it does52 but more recent ones have challenged this claim53, providing the sufficient 
scientific evidence to prove their stand. 
 
One of the most affected or influenced tissues is the adipose tissue since adipocytes are one 
of the most highly insulin-responsive cell types54. Recent studies suggest that defective 
signaling from insulin receptors is associated to the insulin resistance in obese individuals. 
The cause behind it might be an increased expression and activity of several protein tyrosine 
phosphatases (PTPs), with a dephosphorylating function, therefore terminating signaling 
propagated through tyrosine phosphorylation and not allowing GLUT4 to translocate and take 
glucose in (Fig. 6).  
 
Figure 6. Adapted from: Insulin signaling pathway55. Insulin binds to the insulin receptor located in the plasma 
membrane in tissues, such as liver, fat and muscle. The insulin-signaling pathway is activated and the glucose 
transporter GLUT4 is translocated to the plasma membrane. When PTP is active it stops the cascade at the very 




Adipose tissue promotes IR through various inflammatory mechanisms, including increased 
free fatty acid (FFA) release and adipokine deregulation as described in the previous chapter. 
Evolving data suggests that adipokine deregulation, inflammation, abnormalities in gut 
microbiota, immune dysregulation, and inflammation have emerged as important 
pathophysiological factors in the development of T2DM56. There are both environmental 
factors such as diet changes or sedentary lifestyle and genetic factors which are of polygenic 
nature, with certain patterns of IR, reduced insulin secretion and altered insulin processing 
revealed by GWAS over the last decade.  
 
T2DM has several complications or outcomes, all negative for the system. A dyslipidemic 
profile consisting of elevated levels of triglycerides and low density lipoproteins (LDLs) and of 
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diminished levels of high density lipoproteins (HDLs) is tied to T2DM. Lipoprotein production, 
metabolism, and clearance are usually efficient processes. However, T2DM and IR are the 
most important disruptors of these processes and they give rise to impaired metabolism and 
clearance of these lipoproteins, ultimately leading to atherosclerosis57.  
 
One of the primary abnormalities in IR is impaired adipose tissue fat storage, resulting from 
insulin’s inability to inhibit hormone-sensitive lipase (HSL). This results in constitutive free fatty 
acids (FFA) release from the intracellular TG stores of adipocytes (Fig. 7). These FFA’s final 
destinations vary among undergoing β-oxidation in hepatocytes mitochondria, being used to 
assemble new lipoprotein particles, partaking in gluconeogenesis leading to a worsening of 







Figure 7. Image depicting the communication between the liver and muscle and adipose tissue in an insulin 
resistance situation59. The adipose tissue causes the elevated plasma FFA levels when altered, affecting the liver 
and muscle leading to hyperglycemia. The pancreas tries to keep up with the insulin production and eventually 
there is a loss of β.-cell function. 
 
 
6.3 Progression of T2DM increasing the risk of CVD 
 
The increase in production of very low density lipoproteins (VLDLs) by the liver is a crucial 
feature of diabetic dyslipidemia, and it circles back to insulin resistance. These particles are 
synthesized bound to apoB100, and the production and secretion of the VLDL-apoB100 
tandem is directly inhibited through the inhibition of the transcription of the microsomal transfer 
protein (MTP)60. This protein is responsible for the assembly of lipoproteins with apoB100, 
which generates an immature VLDL-apoB100 that will need to be processed by the 
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phospholipase D1 (PLD1). By inhibiting MTP insulin stops this process, therefore stopping the 
overproduction of lipoproteins in a fed state. In IR condition MTP expression is not modified, 
since the acute insulin-mediated inhibition of apoB100 secretion is not working as it should61. 
 
The reduced HDL levels are due to an insulin response element in the gene that codes for 
apoA-I, which is the main apolipoprotein component of the HDL particles. The more insulin 
resistant the liver becomes, the less apoA-I is produced, meaning that there will be a shortage 
in the synthesis of HDL particles. Moreover, in the milieu of IR, HDL particles are not only in 
low concentrations, but they are also often dysfunctional. This prevents HDL from performing 
basic functions such as reversal of cholesterol transport and inhibition of oxidative and 
inflammatory processes62 (Fig. 8). 
 
 
Figure 8. Adapted from: Image depicting how diabetes alters HDL composition and function63. In diabetes, high 
levels of oxidative stress and reactive oxygen species (ROS), induce direct or indirect compositional changes in 
HDL particles, rendering them dysfunctional. Thereby HDL is less effective in extracting cholesterol from cells. 
 
 
This dyslipidemic profile is closely linked to the development and progression of 
atherosclerosis and is a clear contributor of CVDs (Fig. 9). In fact, CVD is responsible for at 
least half of the mortality in the population suffering from T2DM64.  
 
 





Figure 9. Relative risk of CVD in normoglycemia, pre-diabetes, and type 2 diabetes65. As T2DM progresses, issues 
such as IR and hyperglycemia become increasingly more severe, reaching the point of the risk of CVD being slightly 
over three-fold the standard risk. 
 
 
7. CHANGES IN MICROBIOTA 
Obesity is closely related to the gut microbiota. The study of the gut microbiome suggests a 
new line of treatment by reconstructing the gut microbiota of obese individuals.  
 
The gut microbiota comprises up to 100 trillion symbiotic microbes. For the sake of 
comparison, this number is ten times the number of living cells that form the body. Their 
sources of nutrients are food residues not digested by the human body, mucus secreted by 
the gut and dead cells that occasionally detach from the gut itself.   
 
The importance of gut microbiota lies in the many active and beneficial substances that it 
produces in healthy state, such as vitamins, short-chain fatty acids, anti-inflammatory, 
analgesic, and antioxidant products. However it has the potential of producing harmful 
substances such as neurotoxins, carcinogens, and immunotoxins66. All of these can access 
the bloodstream directly from the gut, therefore an imbalance in the gut microbiota, also known 
as dysbiosis, regulates many processes and can cause metabolic disorders, increase central 
appetite and ultimately lead to an obese state67. 
 
Modern technologies of 16S RNA sequencing have allowed in-depth study of the gut 
microbiota.  So far  6457 different taxa have been identified by the gutMEGA database68. The 
standard gut microbiota of the healthy individual is mainly composed of Firmicutes, 
Bacteroides, Proteus, Actinomycetes, Fusobacteria, and Verrucomicrobia. Out of all of them, 
Firmicutes and Bacteroides stand out as the dominating phyla. Signs of healthy microbiota 
include a flexible equilibrium or resilience, meaning the ability to recover from alterations and 
return to a healthy state; diversity, as demonstrated by the many phyla that share livelihood in 
the gut and also the adequate metabolization of polysaccharides, production of SCFA (or short 
chain fatty acids) and production of vitamins and essential amino acids69. The role of SCFA is 
not yet clear, they stand as a double-edged sword. Although they often protect against diet—
induced obesity, it is suggested that an excessive quantity could promote obesity due to being 
used as a source of energy themselves67. 




Firmicutes/Bacteroides is a ratio that is often used a biomarker for obesity, however there is 
some controversy on the relevance of this Firmicutes/Bacteroides ratio when it comes to its 
direct correlation to obesity. Some studies show a direct correlation in the increase of 
Firmicutes over Bacteroides with BMI70, whereas other studies find no difference in this ratio 
when comparing it in healthy and obese individuals71. More research is needed in order to 
determine the precise association between this ratio and obesity. 
 
There are however many genera with established relation to obesity. Christensenellaceae is 
a recently described family in the Firmicutes phylum, which throughout several different 
populations and studies has proven to have an inverse correlation to host BMI. It is in fact the 
most robust link reported to date72. Other genera like Akkermansia muciniphila has proven to 
improve metabolic parameters in obese individuals73. Lactobacillus and Bifidobacterium have 
traditionally been used as probiotics due to their effectiveness in improving the balance of the 
gut microbiota. 
 
Several obesity mechanisms have been found to be induced by the gut microbiota, including 
but not limited to: energy absorption, central appetite, fat storage, chronic inflammation and 
circadian rhythm alterations. 
 
Different studies with mice have demonstrated that individuals with obese gut microbiota 
profiles have, in fact, an increased capacity of extracting energy from the diet. This information 
was confirmed by multiomics analysis, reaching the conclusion that obese type microbiota 
increases lipid absorption in the host7475. This situation predisposes the individual to excessive 
energy accumulation, finally resulting in weight gain.  
 
The gut-brain axis is a strong connection that modulates the interactions between both of 
them. The communication happens through endocrine, immune, and neural pathways. The 
central nervous system affects the composition of gut microbiota, as well as the microbiota 
can influence and regulate brain function when it comes to appetite. It participates in this 
regulation through serotonin, lactate, which is produced by Lactobacillus and Bifidobacterium 
and can extend the duration of satiety76; and anorexic hormones such as peptide YY and 
pancreatic polypeptide. In general, the metabolites of a proper working microbiota are 
associated to a satiety feeling. 
 
As gut microbiota increases the absorption of glucose in the intestine, it increases the level of 
serum glucose, thereby promoting the expression of two factors that promote lipogenesis and 
fat storage: ChREBP (carbohydrate response element binding protein) and SREBP-1 (sterol 
regulatory element binding protein)67. 
 
A healthy microbiota synthesizes the right amounts and kinds of SCFAs, meaning that it will 
produce butyrate, an anti-inflammatory metabolite not only known for suppressing pathways 
leading to the production of pro-inflammatory cytokines but also for the stimulation of energy 
consumption, thus having a double action against the development of obesity77. However, as 
mentioned before, SCFAs do not have a one-sided role, and the perfect example is acetate. 
On the one hand, acetate can be used as a substrate for cholesterol synthesis, thus helping 
to raise serum cholesterol levels, which can increase the risk of obesity. On the other hand, 
acetate has been reported to suppress appetite and reduce the risk of obesity67. 




Studies regarding gut microbiota and its ties to obesity are often limited by the many factors 
conditioning obesity, highlighting as well that variability among individuals and bacteria strains 
could explain the contradicting results. Despite what has been stated, the fact that a clear 
relation exists between gut microbiota and obesity is acknowledged worldwide67. 
 
All of the above perfectly exemplifies how gut microbiota is very much involved in regulating 
and modulating certain obesity mechanisms such as energy uptake and management or 
inflammation (Fig. 10). Further investigation will be needed to shed light into these and many 
other molecular mechanisms that interconnect creating a complex yet precise regulation 
network, which can result in obesity and its associated consequences when genetic and 
environmental factors combine for the worst. 
 
 
Figure 10. Adapted from: illustration depicting the load of microbiota along the gastrointestinal (GI) tract78. In obese 
subjects, alterations in gut microbiota composition result in increased enhanced harvest from the diet, increased 
bacterial translocation, and a decrease in butyrate production. This induces several metabolic changes in 
peripheral tissues, including increased lipogenesis, gluconeogenesis, adipogenesis and inflammation. The immune 
system plays a key role in mediating metabolic effects of the gut microbiota. 
 
 
8. OBESITY AND COVID-19 
In December 2019, a new virus was identified in Wuhan, China. It was named SARS-CoV-2 
(short for severe acute respiratory syndrome coronavirus 2). SARS-CoV-2 causes different 
respiratory symptoms, ranging from non-severe cold-like symptoms to acute pneumonia. It 
has widely and rapidly expanded throughout the whole globe, causing a public health and 
economic crisis. Similar to other respiratory diseases, and according to the WHO, COVID-19 
is often more severe in people older than 60 years or in those individuals who have health 
conditions like lung or heart disease, T2DM or conditions that affect their immune system79. 
 
As previously discussed in detail, T2DM is very closely related to obesity, so the question 
arises if obesity and severity of COVID-19 or higher mortality are linked in any way. It has 
been attempted to answer by systematic reviews and meta-analysis, finally reaching the 
conclusion through careful processing of the data that obesity is, in fact, associated with a 
more severe COVID-19 disease course (Fig. 11). Obese patients are 1.7 times more likely to 
be hospitalized and 1.3 times more likely to be admitted to the intensive care unit (ICU). It is 
not however demonstrated that obesity increases the mortality associated to COVID-1980.  
 




Figure 11. Adapted from: weight disaggregated data of patents of a study of 230 Egyptian COVID-19 patients81. 
 
 
9. FUTURE AND PRESENT RESEARCH 
There are plethora of mechanisms and processes that are not fully understood yet, meaning 
more investigation needs to be carried out in the field in order to elucidate these missing details 
and find solutions to existing problems. These investigation lines are: the excess of type IV 
collagen as a determinant factor in metabolyc dysregulations, steps that occur since the 
expression of HIF-1 α and lead to the fibrosis of the adipose tissue, correlation between levels 
of resistin and obesity, precise role of SCFAs and their mechanisms of action and finally taking 
advantage of gut microbiota sequencing to design new lines of treatment for obese patients.  
 
10. CONCLUSSIONS 
 Obesity is not just turning, but it is already a serious problem in the first world countries. 
The causes are genetic and environmental, meaning that at part of it is definitely 
preventable, therefore individuals and health officials must take a step forward in 
fighting this disease. 
 
 Obesity is not a simple disease, it is in fact multifactorial and extremely hard to 
comprehend to the last detail. It is known however that the adipose tissue, thought to 
be just for fat storage not so long ago, plays a key role in the regulation and 
development of obesity through its increase in size, secretion of cytokines and 
inflammation and fibrosis processes.  
 
 The consequences of obesity are not to be taken lightly, since they impair obese 
patients in several different ways. It is not only about the difficulty to perform everyday 
tasks, but it is about the internal conditions the body is exposed to, such as 
hyperglycemia, dyslipidemia and insulin resistance. These take a huge toll on the 
system and end up having serious consequences such as the increased risk of CVDs, 
the development of T2DM and many other different complications including the 
elevated risk of developing cancer as well. 
 
 The gut microbiota also plays an active role in regulating energy extraction from the 
diet and mediation of chronic inflammation through metabolites such as butyrate and 
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SCFAs. The gut-brain axis works both ways, the gut influencing satiety sensation and 
the brain being able to shape the microbiota. It is key to maintain a healthy gut 
microbiota and preserve the existing flexible equilibrium, because not only helps the 
processes mentioned above, but also keeps the immune system fully functional and 
operational. 
 
 There exists a proven increased risk of suffering complications and having a tougher 
time while suffering from COVID-19 if the patient is obese. This risk is of considerable 
magnitude and it ought not to be underestimated by the risk groups, which include 
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